Loading
PDBj
MenuPDBj@FacebookPDBj@X(formerly Twitter)PDBj@BlueSkyPDBj@YouTubewwPDB FoundationwwPDB
RCSB PDBPDBeBMRBAdv. SearchSearch help

3ZWS

Structure of Human Dihydroorotate Dehydrogenase with a Bound Inhibitor

Summary for 3ZWS
Entry DOI10.2210/pdb3zws/pdb
Related1D3G 1D3H 2B0M 2BXV 2WV8 3ZWT
DescriptorDIHYDROOROTATE DEHYDROGENASE (QUINONE), MITOCHONDRIAL, FLAVIN MONONUCLEOTIDE, OROTIC ACID, ... (8 entities in total)
Functional Keywordsoxidoreductase
Biological sourceHOMO SAPIENS (HUMAN)
Cellular locationMitochondrion inner membrane; Single-pass membrane protein: Q02127
Total number of polymer chains1
Total formula weight41155.86
Authors
Acklam, P.A.,Parsons, M.R. (deposition date: 2011-08-02, release date: 2012-06-27, Last modification date: 2024-05-08)
Primary citationBedingfield, P.T.P.,Cowen, D.,Acklam, P.A.,Cunningham, F.,Parsons, M.R.,Mcconkey, G.A.,Fishwick, C.W.G.,Johnson, A.P.
Factors Influencing the Specificity of Inhibitor Binding to the Human and Malaria Parasite Dihydroorotate Dehydrogenases.
J.Med.Chem., 55:5841-, 2012
Cited by
PubMed Abstract: The de novo pyrimidine biosynthesis enzyme dihydroorotate dehydrogenase is an emerging drug target for the treatment of malaria. In this context a key property of Plasmodium falciparum DHODH (PfDHODH) is that it can be selectively inhibited over its human homologue (HsDHODH). However, HsDHODH is also a validated drug target for autoimmune diseases such as arthritis. Here a series of novel inhibitors is described that includes compounds that switch specificity between the two enzymes as a result of small alterations in chemical structure. Structure-activity relationship (SAR), crystallography, docking, and mutagenesis studies are used to examine the binding modes of the compounds within the two enzymes and to reveal structural changes induced by inhibitor binding. Within this series, compounds with therapeutically relevant HsDHODH activity are described and their binding modes characterized using X-ray crystallography, which reveals a novel conformational shift within the inhibitor binding site.
PubMed: 22621375
DOI: 10.1021/JM300157N
PDB entries with the same primary citation
Experimental method
X-RAY DIFFRACTION (1.6 Å)
Structure validation

227344

PDB entries from 2024-11-13

PDB statisticsPDBj update infoContact PDBjnumon